Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPL | P06858 | 1/20 | 0.34 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.34 |
| ▸ | EGFR | P00533 | 2/20 | 0.32 |
| ▸ | JAK2 | O60674 | 1/20 | 0.30 |
| ▸ | BTK | Q06187 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23409410 | 0.85 | LPL (0.35) | LPLLIPGEGFRJAK2BTK | |
| SCHEMBL23409416 | 0.83 | LPL (0.36) | LPLLIPGEGFRJAK2BTK | |
| SCHEMBL18949792 | 0.80 | BACE1 (0.36) | LPLLIPGEGFRJAK2BTK | |
| SCHEMBL14956069 | 0.79 | LPL (0.36) | LPLLIPGEGFRJAK2BTK | |
| SCHEMBL25427908 | 0.78 | LPL (0.33) | LPLLIPG | |
| SCHEMBL29490857 | 0.78 | LPL (0.33) | LPLLIPG | |
| SCHEMBL22120177 | 0.77 | LPL (0.34) | LPLLIPGEGFR | |
| SCHEMBL30198023 | 0.76 | GRM5 (0.34) | LPLLIPGEGFR | |
| SCHEMBL17775103 | 0.76 | GRM5 (0.34) | LPLLIPGEGFR | |
| SCHEMBL28768446 | 0.76 | LPL (0.33) | LPLLIPGEGFRJAK2BTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12466781-B2 | Thyromimetics | AUTOBAHN THERAPEUTICS, INC. (US) | 2025-11-11 | — | — | US | disclosed |
| WO-2024173343-A1 | COMPOUNDS TARGETING HYDROXYSTEROID 17-BETA DEHYDROGENASE (HSD17B) AND USES THEREOF | REGENERON PHARMACEUTICALS, INC. (US) | 2024-08-22 | — | — | WO | disclosed |
| US-20230048992-A1 | NOVEL THYROMIMETICS | AUTOBAHN THERAPEUTICS, INC. | 2023-02-16 | — | — | US | disclosed |
| US-20230048992-A1 | NOVEL THYROMIMETICS | AUTOBAHN THERAPEUTICS, INC. | 2023-02-16 | — | — | US | disclosed |
| CN-115279359-A | Novel thyromimetic agents | 速通医疗公司 | 2022-11-01 | — | — | CN | disclosed |
| EP-4065098-A1 | NOVEL THYROMIMETICS | Autobahn Therapeutics, Inc. (US) | 2022-10-05 | — | — | EP | disclosed |
| WO-2021108549-A1 | NOVEL THYROMIMETICS | AUTOBAHN THERAPEUTICS, INC. (US) | 2021-06-03 | — | — | WO | disclosed |
| WO-2021108549-A1 | NOVEL THYROMIMETICS | AUTOBAHN THERAPEUTICS, INC. (US) | 2021-06-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230048992-A1 | NOVEL THYROMIMETICS | TSHR, TPO, CHRM1 | LPL 2750/4885LIPG 3804/4885EGFR 2344/4885 |
| US-12466781-B2 | Thyromimetics | TPO, TSHR, CHRM1 | LPL 2669/4885LIPG 3784/4885EGFR 2495/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.